COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Orogen Royalties Provides Year-End Royalty Update and 2024 Forecast
Orogen Royalties Inc. provides a 2023 year-end update on its royalty portfolio and forecast for 2024, including production data from Ermitaño mine in Mexico and the Expanded Silicon project in Nevada, as well as advancements on various other royalty assets -
COMMUNIQUÉ DE PRESSE
Results of First General Meeting
Arix Bioscience PLC announces results of the first general meeting and the passing of a special resolution to approve the recommended all-share acquisition by RTW Biotech Opportunities Ltd. The second general meeting is scheduled for 12 February 2024 -
COMMUNIQUÉ DE PRESSE
Applied UV Inc. Announces Receipt of Provisional Patent for Our Pulse Modulated UVC LED System to be Added to Our Patented Fighter Flex LED Solution Expanding Significant Revenue Opportunity
Applied UV Inc. introduces pulse modulated UVC LED enhancement to Fighter Flex LED solution, expanding revenue opportunity in HVAC industry. Major potential for energy and cost savings -
COMMUNIQUÉ DE PRESSE
Komet Sales and Axerrio Combine to Expand Their Leading B2B Floral E-Commerce Network Across Europe and the Americas
Komet Sales, the leading software provider for the floral industry in the Americas, announces merger with Axerrio, a leading software provider for the floral industry in Europe. The merger aims to benefit customers by increasing access to new features and an expanded network of buyers and sellers -
COMMUNIQUÉ DE PRESSE
Cotec Holdings Corp. Provides Operational Overview and 2024 Key Targets
CoTec Holdings Corp. (TSXV:CTH)(OTCQB:CTHCF) reports 2023 operational highlights and 2024 targets. Initiated strategic investments, completed name change, and listed on TSXV. Focus on sustainable resource production and transformative technologies -
-
COMMUNIQUÉ DE PRESSE
Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found
NanoViricides, Inc. successfully completes Phase 1a/1b Clinical Trial of NV-CoV-2, reporting excellent safety and broad-spectrum antiviral activity of NV-387 against various respiratory viruses including Coronaviruses and RSV -
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Bilfinger SE: EBITA margin and free cash flow in financial year 2023 exceeded outlook
Bilfinger SE reports EBITA margin for 2023 financial year exceeded outlook at 4.3% and free cash flow expected to be € 122 million, surpassing outlook by € 42 million. Revenue to be within outlook range. Mid-term targets confirmed
